Microsatellite Instability-High Cancer
FDA approves FoundationOne CDx to identify patients with MSI-high tumors for pembrolizumab
The FDA approved FoundationOne CDx as a companion diagnostic to identify patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab, according to a press release from the test’s manufacturer.
FDA approves Keytruda as first-line treatment for colorectal cancer subtype
The FDA approved pembrolizumab for first-line treatment of patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient colorectal cancer.
Pembrolizumab doubles PFS for certain patients with metastatic colorectal cancer
First-line pembrolizumab extended PFS vs. chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to findings to be presented during the ASCO20 Virtual Scientific Program.
FDA announces international collaboration, approves pembrolizumab plus lenvatinib for endometrial cancer
The FDA, in conjunction with decisions by regulatory agencies in Australia and Canada, granted accelerated approval to pembrolizumab in combination with lenvatinib for the treatment of certain women with advanced endometrial carcinoma, according to a press release from the agency.